A new drug-eluting stent designed to increase the antirestenotic performance of the paclitaxel-eluting stent and decrease the risk of stent thrombosis by incorporating cilostazol, is safe and effective in decreasing late loss, according to Seung-Jung Park and colleagues at Asan Medical Center in Seoul, South Korea.
Results of the small randomised trial, “Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions,” have recently been published in the American Journal of Cardiology.
The study randomised 111 patients undergoing percutaneous coronary intervention for de novo coronary artery lesions. Fifty five patients received Cilotax and 56 received Taxus Liberte stents. Primary endpoint was in-segment late loss at eight months.
Baseline characteristics were similar for the two groups. The Cilotax stent was not inferior to Taxus Liberte stent as determined by in-segment late loss (0.28±0.30 vs. 0.42±0.45mm, difference -0.14, 95% confidence interval -0.27 to -0.01, 1-sided p=0.028 for non-inferiority).
There was no stent thrombosis at eight months in either group. Rates of death, myocardial infarction, and any target lesion revascularisation at eight months were 0%, 0%, and 1.9%, respectively, in the Cilotax group, and 1.8%, 0% and 3.6%, respectively, in the Taxus Liberte group.
“In-stent late loss was significantly lower in the Cilotax than in the Taxus Liberte group (0.22±0.31 vs. 0.50 ± 0.55mm, p=0.002). Although in-segment restenosis rate did not differ significantly between the two groups (3.8% vs. 10.9%, respectively, p=0.271), in-stent restenosis rate was significantly lower in the Cilotax stent group (0% vs. 10.9%, p=0.027),” investigators reported.
